VERU INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
VERU INC. (VERU) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-09-30, per its 10-K filed 2024-12-16.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-12-16
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $21.92K.
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $286.81K, a 93.50% decline from fiscal 2022.
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $4.41M.
- VERU INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $1.67M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $0.00 10-K · filed 2024-12-16 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2023-09-30 | $21.92K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $21.92K derived: sum of 2 quarters · filed 2024-12-16 | $286.81K 10-K · filed 2024-12-16 | |
| 2023-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | $264.90K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $264.90K 10-Q · filed 2024-05-08 | |||
| 2022-09-30 | $0.00 derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2024-04-01 | $18.89K derived: sum of 2 quarters · filed 2024-04-01 | $4.41M 10-K/A · filed 2024-04-01 | |
| 2022-06-30 | $18.89K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-11-15 | $4.41M 10-Q/A · filed 2023-11-15 | ||
| 2022-03-31 | $4.39M 10-Q · filed 2023-05-11 | |||
| 2020-09-30 | $419.98K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $443.29K derived: sum of 2 quarters · filed 2021-12-02 | $443.29K derived: sum of 3 quarters · filed 2021-12-02 | $1.67M 10-K · filed 2021-12-02 |
| 2020-06-30 | $23.31K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-12 | $23.31K derived: sum of 2 quarters · filed 2021-08-12 | $1.25M 10-Q · filed 2021-08-12 | |
| 2020-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-12 | $1.23M 10-Q · filed 2021-05-12 | ||
| 2019-12-31 | $1.23M 10-Q · filed 2021-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |